 Dara Aisner
Concepts (418)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Neoplasms | 67 | 2025 | 2526 | 4.900 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 46 | 2025 | 1081 | 3.880 |
Why?
| | ErbB Receptors | 22 | 2025 | 614 | 2.230 |
Why?
| | Genetic Testing | 9 | 2022 | 460 | 2.230 |
Why?
| | Mutation | 41 | 2025 | 3958 | 2.080 |
Why?
| | Pathology, Molecular | 7 | 2019 | 27 | 2.020 |
Why?
| | High-Throughput Nucleotide Sequencing | 15 | 2025 | 539 | 1.910 |
Why?
| | Oncogene Proteins, Fusion | 13 | 2019 | 215 | 1.890 |
Why?
| | Protein Kinase Inhibitors | 26 | 2025 | 916 | 1.760 |
Why?
| | Molecular Diagnostic Techniques | 3 | 2020 | 105 | 1.560 |
Why?
| | Neoplasms | 13 | 2025 | 2671 | 1.390 |
Why?
| | Proto-Oncogene Proteins B-raf | 13 | 2022 | 224 | 1.380 |
Why?
| | Proto-Oncogene Proteins | 17 | 2018 | 648 | 1.360 |
Why?
| | Protein-Tyrosine Kinases | 12 | 2018 | 434 | 1.310 |
Why?
| | Biomarkers, Tumor | 18 | 2024 | 1276 | 1.130 |
Why?
| | Receptor Protein-Tyrosine Kinases | 10 | 2019 | 234 | 1.070 |
Why?
| | DNA, Neoplasm | 3 | 2019 | 164 | 1.060 |
Why?
| | Antineoplastic Agents | 16 | 2024 | 2129 | 1.030 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 11 | 2020 | 267 | 1.010 |
Why?
| | Proto-Oncogene Proteins c-met | 5 | 2019 | 75 | 0.910 |
Why?
| | Drug Resistance, Neoplasm | 13 | 2023 | 801 | 0.910 |
Why?
| | Acrylamides | 5 | 2025 | 57 | 0.810 |
Why?
| | Gene Rearrangement | 13 | 2019 | 150 | 0.800 |
Why?
| | Colorectal Neoplasms | 3 | 2022 | 806 | 0.800 |
Why?
| | Adenocarcinoma | 9 | 2018 | 940 | 0.770 |
Why?
| | Molecular Targeted Therapy | 11 | 2024 | 411 | 0.740 |
Why?
| | Ganglioglioma | 4 | 2014 | 35 | 0.730 |
Why?
| | Brain Neoplasms | 10 | 2018 | 1238 | 0.710 |
Why?
| | DNA Mutational Analysis | 11 | 2020 | 399 | 0.700 |
Why?
| | Aniline Compounds | 4 | 2025 | 102 | 0.680 |
Why?
| | Humans | 125 | 2025 | 137585 | 0.660 |
Why?
| | Precision Medicine | 4 | 2018 | 429 | 0.650 |
Why?
| | Adenocarcinoma, Mucinous | 2 | 2022 | 80 | 0.630 |
Why?
| | Pyrazoles | 10 | 2018 | 423 | 0.630 |
Why?
| | Insurance, Health, Reimbursement | 1 | 2020 | 99 | 0.630 |
Why?
| | Neoplasms, Muscle Tissue | 1 | 2019 | 4 | 0.630 |
Why?
| | Receptors, Nerve Growth Factor | 1 | 2019 | 17 | 0.620 |
Why?
| | Immunohistochemistry | 10 | 2023 | 1738 | 0.620 |
Why?
| | Biological Products | 1 | 2022 | 216 | 0.610 |
Why?
| | Prognosis | 14 | 2024 | 4030 | 0.610 |
Why?
| | Astrocytoma | 3 | 2015 | 128 | 0.600 |
Why?
| | Neoplasm Metastasis | 10 | 2024 | 658 | 0.600 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 7 | 2024 | 1692 | 0.600 |
Why?
| | Insurance Coverage | 1 | 2020 | 230 | 0.590 |
Why?
| | In Situ Hybridization, Fluorescence | 13 | 2019 | 317 | 0.560 |
Why?
| | Laboratory Proficiency Testing | 2 | 2023 | 10 | 0.560 |
Why?
| | Computational Biology | 4 | 2023 | 644 | 0.530 |
Why?
| | RNA | 5 | 2019 | 921 | 0.480 |
Why?
| | Tumor Suppressor Protein p53 | 3 | 2023 | 528 | 0.480 |
Why?
| | Small Cell Lung Carcinoma | 1 | 2016 | 96 | 0.450 |
Why?
| | Neoplasm Staging | 13 | 2024 | 1389 | 0.440 |
Why?
| | Pyrimidines | 6 | 2025 | 470 | 0.430 |
Why?
| | ras Proteins | 5 | 2015 | 153 | 0.430 |
Why?
| | Smoking | 3 | 2018 | 1627 | 0.430 |
Why?
| | Aged, 80 and over | 18 | 2025 | 7635 | 0.420 |
Why?
| | Pyridines | 8 | 2016 | 506 | 0.420 |
Why?
| | Mesothelioma | 2 | 2024 | 44 | 0.410 |
Why?
| | Neoplasm Recurrence, Local | 3 | 2022 | 1079 | 0.390 |
Why?
| | AMP-Activated Protein Kinases | 1 | 2014 | 197 | 0.380 |
Why?
| | Aged | 32 | 2025 | 23961 | 0.370 |
Why?
| | Laboratories | 3 | 2025 | 113 | 0.360 |
Why?
| | Male | 52 | 2025 | 67762 | 0.360 |
Why?
| | Female | 53 | 2025 | 73304 | 0.360 |
Why?
| | Telomerase | 7 | 2002 | 250 | 0.350 |
Why?
| | S100 Proteins | 2 | 2014 | 37 | 0.350 |
Why?
| | Neoadjuvant Therapy | 3 | 2024 | 404 | 0.350 |
Why?
| | Middle Aged | 40 | 2025 | 33479 | 0.350 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2014 | 412 | 0.340 |
Why?
| | Pleural Neoplasms | 2 | 2024 | 25 | 0.340 |
Why?
| | Genomics | 4 | 2023 | 795 | 0.320 |
Why?
| | Sulfones | 3 | 2015 | 110 | 0.310 |
Why?
| | Medical Oncology | 4 | 2025 | 289 | 0.310 |
Why?
| | Glycine | 3 | 2015 | 176 | 0.310 |
Why?
| | Curriculum | 1 | 2016 | 992 | 0.300 |
Why?
| | Early Detection of Cancer | 2 | 2019 | 447 | 0.300 |
Why?
| | Adult | 35 | 2025 | 37929 | 0.280 |
Why?
| | Adrenal Gland Neoplasms | 2 | 2022 | 89 | 0.280 |
Why?
| | Head and Neck Neoplasms | 3 | 2019 | 606 | 0.270 |
Why?
| | Neoplasms, Multiple Primary | 2 | 2022 | 57 | 0.270 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 4 | 2022 | 95 | 0.260 |
Why?
| | Oncogene Fusion | 2 | 2019 | 13 | 0.260 |
Why?
| | Indoles | 5 | 2025 | 412 | 0.260 |
Why?
| | Treatment Outcome | 12 | 2024 | 10811 | 0.260 |
Why?
| | Gene Dosage | 2 | 2018 | 140 | 0.260 |
Why?
| | Receptor, Fibroblast Growth Factor, Type 1 | 2 | 2018 | 53 | 0.260 |
Why?
| | Exons | 5 | 2019 | 355 | 0.260 |
Why?
| | Antineoplastic Agents, Immunological | 2 | 2018 | 190 | 0.250 |
Why?
| | Survival Analysis | 5 | 2025 | 1325 | 0.250 |
Why?
| | Melanoma | 2 | 2020 | 760 | 0.250 |
Why?
| | Phosphatidylinositol 3-Kinases | 4 | 2023 | 366 | 0.240 |
Why?
| | Genetic Predisposition to Disease | 6 | 2019 | 2426 | 0.240 |
Why?
| | Oncogenes | 3 | 2016 | 116 | 0.240 |
Why?
| | Thymus Neoplasms | 1 | 2025 | 25 | 0.240 |
Why?
| | Sodium-Phosphate Cotransporter Proteins, Type IIb | 3 | 2015 | 9 | 0.240 |
Why?
| | Thymoma | 1 | 2025 | 36 | 0.240 |
Why?
| | Receptor, ErbB-2 | 4 | 2022 | 341 | 0.230 |
Why?
| | Pemetrexed | 1 | 2024 | 33 | 0.230 |
Why?
| | Epithelioid Cells | 2 | 2015 | 9 | 0.230 |
Why?
| | Immunotherapy | 5 | 2022 | 641 | 0.220 |
Why?
| | Fetomaternal Transfusion | 1 | 2023 | 11 | 0.210 |
Why?
| | Sensitivity and Specificity | 5 | 2019 | 1946 | 0.210 |
Why?
| | Carcinoma, Squamous Cell | 3 | 2019 | 683 | 0.200 |
Why?
| | Choriocarcinoma | 1 | 2022 | 9 | 0.200 |
Why?
| | Endodermal Sinus Tumor | 1 | 2022 | 9 | 0.200 |
Why?
| | Tertiary Care Centers | 1 | 2023 | 160 | 0.200 |
Why?
| | Cell Line, Tumor | 11 | 2018 | 3412 | 0.200 |
Why?
| | Pathologists | 2 | 2023 | 18 | 0.190 |
Why?
| | Young Adult | 13 | 2024 | 13209 | 0.190 |
Why?
| | Goals | 1 | 2023 | 170 | 0.190 |
Why?
| | Biopsy, Fine-Needle | 2 | 2012 | 68 | 0.190 |
Why?
| | Gene Fusion | 2 | 2018 | 27 | 0.180 |
Why?
| | Patient Selection | 4 | 2018 | 696 | 0.180 |
Why?
| | Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2022 | 35 | 0.180 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 1 | 2022 | 77 | 0.180 |
Why?
| | Cell Proliferation | 7 | 2017 | 2475 | 0.180 |
Why?
| | Hematologic Neoplasms | 1 | 2023 | 156 | 0.180 |
Why?
| | United States | 10 | 2025 | 14841 | 0.180 |
Why?
| | Graft vs Host Disease | 1 | 2023 | 252 | 0.180 |
Why?
| | Trastuzumab | 1 | 2021 | 96 | 0.180 |
Why?
| | Pheochromocytoma | 1 | 2022 | 59 | 0.180 |
Why?
| | Biopsy | 4 | 2018 | 1129 | 0.180 |
Why?
| | Combined Modality Therapy | 4 | 2018 | 1236 | 0.180 |
Why?
| | Endometrial Neoplasms | 1 | 2023 | 201 | 0.180 |
Why?
| | Carbazoles | 1 | 2021 | 83 | 0.180 |
Why?
| | Meningioma | 1 | 2022 | 91 | 0.170 |
Why?
| | Glioblastoma | 2 | 2015 | 345 | 0.170 |
Why?
| | Laboratories, Hospital | 1 | 2020 | 15 | 0.170 |
Why?
| | DNA Copy Number Variations | 5 | 2025 | 182 | 0.170 |
Why?
| | Government Regulation | 1 | 2020 | 54 | 0.160 |
Why?
| | Pathology, Clinical | 2 | 2017 | 36 | 0.160 |
Why?
| | GTP Phosphohydrolases | 1 | 2020 | 93 | 0.160 |
Why?
| | Piperidines | 1 | 2021 | 206 | 0.160 |
Why?
| | Costs and Cost Analysis | 1 | 2020 | 213 | 0.160 |
Why?
| | Stakeholder Participation | 1 | 2020 | 78 | 0.160 |
Why?
| | Cell Transformation, Neoplastic | 3 | 2018 | 327 | 0.160 |
Why?
| | Endoscopic Ultrasound-Guided Fine Needle Aspiration | 2 | 2017 | 56 | 0.160 |
Why?
| | Chromosome Aberrations | 2 | 2019 | 156 | 0.150 |
Why?
| | Genes, erbB-2 | 2 | 2015 | 28 | 0.150 |
Why?
| | Smad4 Protein | 1 | 2019 | 38 | 0.150 |
Why?
| | Multiplex Polymerase Chain Reaction | 1 | 2019 | 54 | 0.150 |
Why?
| | Genetic Heterogeneity | 1 | 2019 | 59 | 0.150 |
Why?
| | Multigene Family | 1 | 2019 | 198 | 0.150 |
Why?
| | Breast Neoplasms, Male | 1 | 2018 | 29 | 0.150 |
Why?
| | Genetic Markers | 1 | 2019 | 344 | 0.140 |
Why?
| | Pregnancy Complications | 1 | 2023 | 527 | 0.140 |
Why?
| | Pyridazines | 1 | 2018 | 56 | 0.140 |
Why?
| | Database Management Systems | 1 | 2018 | 51 | 0.140 |
Why?
| | Piperazines | 2 | 2018 | 350 | 0.140 |
Why?
| | Cell Cycle Proteins | 4 | 2015 | 617 | 0.140 |
Why?
| | Gene Frequency | 1 | 2019 | 521 | 0.140 |
Why?
| | Genetic Association Studies | 1 | 2019 | 377 | 0.140 |
Why?
| | Quinazolines | 3 | 2014 | 251 | 0.140 |
Why?
| | Thromboembolism | 1 | 2018 | 119 | 0.140 |
Why?
| | Programmed Cell Death 1 Receptor | 2 | 2018 | 249 | 0.140 |
Why?
| | Cell-Free Nucleic Acids | 1 | 2018 | 43 | 0.140 |
Why?
| | Smokers | 1 | 2018 | 145 | 0.140 |
Why?
| | Skin Neoplasms | 2 | 2020 | 855 | 0.140 |
Why?
| | Imidazoles | 1 | 2018 | 238 | 0.130 |
Why?
| | Gene Deletion | 1 | 2019 | 391 | 0.130 |
Why?
| | Radiotherapy, Intensity-Modulated | 1 | 2018 | 142 | 0.130 |
Why?
| | Intraoperative Care | 1 | 2017 | 52 | 0.130 |
Why?
| | Medical Informatics | 1 | 2018 | 101 | 0.130 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2024 | 630 | 0.130 |
Why?
| | Chloroquine | 1 | 2017 | 54 | 0.130 |
Why?
| | Retrospective Studies | 11 | 2025 | 15657 | 0.130 |
Why?
| | B7-H1 Antigen | 1 | 2018 | 217 | 0.130 |
Why?
| | Ovarian Neoplasms | 1 | 2022 | 565 | 0.130 |
Why?
| | Small Molecule Libraries | 1 | 2017 | 94 | 0.130 |
Why?
| | Pleural Effusion, Malignant | 1 | 2016 | 12 | 0.130 |
Why?
| | Coculture Techniques | 1 | 2017 | 239 | 0.130 |
Why?
| | Clinical Decision-Making | 1 | 2019 | 322 | 0.120 |
Why?
| | Disease Progression | 6 | 2024 | 2757 | 0.120 |
Why?
| | Carcinogenesis | 1 | 2017 | 217 | 0.120 |
Why?
| | Sulfonamides | 2 | 2017 | 513 | 0.120 |
Why?
| | Proto-Oncogene Proteins c-kit | 1 | 2016 | 67 | 0.120 |
Why?
| | Immunity, Humoral | 1 | 2016 | 116 | 0.120 |
Why?
| | Codon | 1 | 2016 | 89 | 0.120 |
Why?
| | RNA, Messenger | 4 | 2018 | 2833 | 0.120 |
Why?
| | Neoplastic Cells, Circulating | 1 | 2016 | 80 | 0.120 |
Why?
| | Triple Negative Breast Neoplasms | 1 | 2018 | 202 | 0.120 |
Why?
| | Positron Emission Tomography Computed Tomography | 1 | 2016 | 98 | 0.120 |
Why?
| | Protein Kinases | 1 | 2017 | 319 | 0.120 |
Why?
| | Peritoneal Neoplasms | 1 | 2016 | 93 | 0.120 |
Why?
| | Oncogene Proteins | 1 | 2015 | 59 | 0.120 |
Why?
| | Fatal Outcome | 1 | 2016 | 303 | 0.120 |
Why?
| | Clinical Laboratory Techniques | 1 | 2016 | 97 | 0.120 |
Why?
| | Signal Transduction | 5 | 2017 | 5079 | 0.120 |
Why?
| | Amino Acid Substitution | 1 | 2016 | 307 | 0.110 |
Why?
| | Hamartoma | 1 | 2015 | 22 | 0.110 |
Why?
| | Immunity, Cellular | 1 | 2016 | 268 | 0.110 |
Why?
| | Practice Guidelines as Topic | 2 | 2019 | 1587 | 0.110 |
Why?
| | Sequence Analysis, RNA | 1 | 2017 | 452 | 0.110 |
Why?
| | Medicare | 1 | 2020 | 773 | 0.110 |
Why?
| | Pharmacogenetics | 1 | 2016 | 180 | 0.110 |
Why?
| | Meningeal Carcinomatosis | 1 | 2014 | 8 | 0.110 |
Why?
| | Genetic Variation | 1 | 2019 | 991 | 0.110 |
Why?
| | Spinal Cord Neoplasms | 1 | 2014 | 37 | 0.110 |
Why?
| | Autophagy | 1 | 2017 | 284 | 0.110 |
Why?
| | Health Care Surveys | 1 | 2016 | 565 | 0.110 |
Why?
| | Speech Disorders | 1 | 2014 | 31 | 0.110 |
Why?
| | Deoxycytidine | 1 | 2015 | 179 | 0.110 |
Why?
| | Paresis | 1 | 2014 | 30 | 0.110 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2015 | 313 | 0.110 |
Why?
| | Multimodal Imaging | 1 | 2015 | 113 | 0.110 |
Why?
| | Receptor, trkA | 1 | 2013 | 18 | 0.110 |
Why?
| | Alternative Splicing | 3 | 2017 | 229 | 0.110 |
Why?
| | Liver Neoplasms | 3 | 2015 | 786 | 0.110 |
Why?
| | Polymerase Chain Reaction | 2 | 2014 | 1062 | 0.110 |
Why?
| | Membrane Proteins | 1 | 2020 | 1164 | 0.110 |
Why?
| | Tumor Cells, Cultured | 5 | 2019 | 955 | 0.110 |
Why?
| | Intracranial Hemorrhages | 1 | 2014 | 85 | 0.100 |
Why?
| | Lung Transplantation | 1 | 2016 | 313 | 0.100 |
Why?
| | Wnt Signaling Pathway | 1 | 2015 | 192 | 0.100 |
Why?
| | Microscopy, Electron | 1 | 2014 | 443 | 0.100 |
Why?
| | Dose-Response Relationship, Drug | 5 | 2021 | 2057 | 0.100 |
Why?
| | Positron-Emission Tomography | 1 | 2015 | 294 | 0.100 |
Why?
| | Serine Endopeptidases | 1 | 2013 | 123 | 0.100 |
Why?
| | Brain Stem Neoplasms | 1 | 2013 | 83 | 0.100 |
Why?
| | Headache | 1 | 2014 | 147 | 0.100 |
Why?
| | Sarcoma | 1 | 2015 | 188 | 0.100 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 4 | 2017 | 976 | 0.100 |
Why?
| | Societies, Medical | 4 | 2018 | 820 | 0.100 |
Why?
| | Graft Rejection | 1 | 2016 | 624 | 0.100 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2019 | 1396 | 0.100 |
Why?
| | Bone Neoplasms | 1 | 2015 | 247 | 0.100 |
Why?
| | Microtubule-Associated Proteins | 1 | 2013 | 196 | 0.100 |
Why?
| | Tissue Fixation | 1 | 2012 | 36 | 0.100 |
Why?
| | Recombinant Fusion Proteins | 2 | 2013 | 665 | 0.100 |
Why?
| | Gene Amplification | 3 | 2019 | 104 | 0.090 |
Why?
| | Predictive Value of Tests | 2 | 2015 | 2031 | 0.090 |
Why?
| | Mutation Rate | 1 | 2011 | 30 | 0.090 |
Why?
| | Lung | 4 | 2015 | 4060 | 0.090 |
Why?
| | Translocation, Genetic | 1 | 2012 | 105 | 0.090 |
Why?
| | Algorithms | 1 | 2019 | 1704 | 0.090 |
Why?
| | Education, Medical, Graduate | 1 | 2016 | 486 | 0.090 |
Why?
| | Interdisciplinary Communication | 1 | 2012 | 191 | 0.090 |
Why?
| | Tomography, X-Ray Computed | 3 | 2018 | 2691 | 0.090 |
Why?
| | Clinical Trials as Topic | 3 | 2025 | 1050 | 0.090 |
Why?
| | Specimen Handling | 1 | 2012 | 183 | 0.090 |
Why?
| | Teratoma | 1 | 2011 | 114 | 0.080 |
Why?
| | Epithelial Cells | 1 | 2017 | 1096 | 0.080 |
Why?
| | Rhabdoid Tumor | 1 | 2011 | 99 | 0.080 |
Why?
| | Terminology as Topic | 1 | 2012 | 216 | 0.080 |
Why?
| | DNA-Binding Proteins | 6 | 2011 | 1502 | 0.080 |
Why?
| | Prospective Studies | 2 | 2023 | 7604 | 0.080 |
Why?
| | Genome, Human | 1 | 2012 | 425 | 0.080 |
Why?
| | Immunoenzyme Techniques | 3 | 2015 | 219 | 0.080 |
Why?
| | Breast Neoplasms | 1 | 2022 | 2253 | 0.080 |
Why?
| | Xenograft Model Antitumor Assays | 3 | 2019 | 872 | 0.080 |
Why?
| | Phosphorylation | 1 | 2014 | 1759 | 0.080 |
Why?
| | Erlotinib Hydrochloride | 3 | 2014 | 72 | 0.080 |
Why?
| | Disease-Free Survival | 3 | 2016 | 686 | 0.080 |
Why?
| | Survival Rate | 4 | 2019 | 1972 | 0.080 |
Why?
| | Catheter Ablation | 1 | 2012 | 350 | 0.080 |
Why?
| | Leukemia-Lymphoma, Adult T-Cell | 1 | 2008 | 14 | 0.070 |
Why?
| | Telomere | 3 | 2000 | 280 | 0.070 |
Why?
| | Proto-Oncogene Proteins c-ret | 2 | 2018 | 36 | 0.070 |
Why?
| | Diagnosis, Differential | 1 | 2012 | 1483 | 0.070 |
Why?
| | Hematopoietic Stem Cell Transplantation | 2 | 2024 | 622 | 0.070 |
Why?
| | beta Catenin | 2 | 2023 | 253 | 0.070 |
Why?
| | Maximum Tolerated Dose | 2 | 2021 | 199 | 0.070 |
Why?
| | Follow-Up Studies | 4 | 2021 | 5131 | 0.070 |
Why?
| | Heart Neoplasms | 1 | 2008 | 50 | 0.070 |
Why?
| | Pancreatic Neoplasms | 1 | 2015 | 938 | 0.070 |
Why?
| | DNA | 1 | 2014 | 1459 | 0.070 |
Why?
| | Adolescent | 6 | 2019 | 21513 | 0.070 |
Why?
| | Reproducibility of Results | 3 | 2019 | 3284 | 0.060 |
Why?
| | Workflow | 2 | 2017 | 165 | 0.060 |
Why?
| | Eye Neoplasms | 1 | 2005 | 18 | 0.060 |
Why?
| | National Cancer Institute (U.S.) | 1 | 2025 | 49 | 0.060 |
Why?
| | Internship and Residency | 1 | 2016 | 1147 | 0.060 |
Why?
| | Mental Disorders | 1 | 2014 | 1077 | 0.060 |
Why?
| | Myasthenia Gravis | 1 | 2025 | 23 | 0.060 |
Why?
| | Pleura | 1 | 2024 | 23 | 0.050 |
Why?
| | Immunophenotyping | 1 | 2005 | 318 | 0.050 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2025 | 2189 | 0.050 |
Why?
| | Administration, Oral | 2 | 2018 | 816 | 0.050 |
Why?
| | Induction Chemotherapy | 1 | 2024 | 76 | 0.050 |
Why?
| | DNA Polymerase II | 1 | 2023 | 37 | 0.050 |
Why?
| | Poly-ADP-Ribose Binding Proteins | 1 | 2023 | 35 | 0.050 |
Why?
| | Peritoneum | 1 | 2023 | 44 | 0.050 |
Why?
| | Genes, ras | 2 | 2015 | 97 | 0.050 |
Why?
| | DNA Mismatch Repair | 1 | 2023 | 49 | 0.050 |
Why?
| | Real-Time Polymerase Chain Reaction | 2 | 2015 | 346 | 0.050 |
Why?
| | Antigens, Differentiation, B-Lymphocyte | 2 | 2013 | 37 | 0.050 |
Why?
| | Leukocyte Count | 1 | 2024 | 329 | 0.050 |
Why?
| | Blotting, Western | 4 | 2015 | 1226 | 0.050 |
Why?
| | Carcinoma, Endometrioid | 1 | 2022 | 50 | 0.050 |
Why?
| | Cell Cycle | 2 | 2012 | 601 | 0.050 |
Why?
| | Cell Survival | 2 | 2017 | 1120 | 0.050 |
Why?
| | Magnetic Resonance Imaging | 1 | 2014 | 3566 | 0.050 |
Why?
| | Active Transport, Cell Nucleus | 1 | 2002 | 124 | 0.050 |
Why?
| | Histocompatibility Antigens Class II | 2 | 2013 | 367 | 0.040 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2002 | 283 | 0.040 |
Why?
| | Models, Molecular | 2 | 2018 | 1570 | 0.040 |
Why?
| | Gene Expression Profiling | 2 | 2017 | 1774 | 0.040 |
Why?
| | Standard of Care | 1 | 2020 | 72 | 0.040 |
Why?
| | Base Sequence | 3 | 2017 | 2181 | 0.040 |
Why?
| | Protein Processing, Post-Translational | 1 | 2002 | 465 | 0.040 |
Why?
| | Catalytic Domain | 4 | 2000 | 207 | 0.040 |
Why?
| | HSP90 Heat-Shock Proteins | 1 | 1999 | 46 | 0.040 |
Why?
| | Time Factors | 3 | 2020 | 6828 | 0.040 |
Why?
| | Fetus | 1 | 2023 | 806 | 0.040 |
Why?
| | Tumor Microenvironment | 1 | 2023 | 674 | 0.040 |
Why?
| | Cell Nucleus | 1 | 2002 | 620 | 0.040 |
Why?
| | Radiotherapy, Image-Guided | 1 | 2018 | 35 | 0.040 |
Why?
| | Sequence Deletion | 2 | 2014 | 183 | 0.040 |
Why?
| | Aurora Kinase A | 1 | 2018 | 56 | 0.040 |
Why?
| | Cell Line | 4 | 2012 | 2847 | 0.040 |
Why?
| | Cohort Studies | 2 | 2019 | 5742 | 0.040 |
Why?
| | Proto-Oncogenes | 1 | 2018 | 29 | 0.040 |
Why?
| | Phthalazines | 1 | 2018 | 45 | 0.040 |
Why?
| | RNA, Untranslated | 1 | 1999 | 124 | 0.040 |
Why?
| | Nausea | 1 | 2018 | 111 | 0.040 |
Why?
| | Cetuximab | 1 | 2018 | 98 | 0.040 |
Why?
| | Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2017 | 27 | 0.030 |
Why?
| | Breast | 1 | 2018 | 151 | 0.030 |
Why?
| | Diarrhea | 1 | 2018 | 184 | 0.030 |
Why?
| | Quality Control | 1 | 2017 | 172 | 0.030 |
Why?
| | A549 Cells | 1 | 2017 | 66 | 0.030 |
Why?
| | Child | 5 | 2015 | 21935 | 0.030 |
Why?
| | Molecular Sequence Data | 3 | 2013 | 2900 | 0.030 |
Why?
| | Pathology, Surgical | 1 | 2016 | 10 | 0.030 |
Why?
| | Structure-Activity Relationship | 1 | 2018 | 570 | 0.030 |
Why?
| | Fatigue | 1 | 2018 | 329 | 0.030 |
Why?
| | Centrosome | 1 | 2016 | 71 | 0.030 |
Why?
| | Drug Synergism | 1 | 2017 | 382 | 0.030 |
Why?
| | Dual Specificity Phosphatase 6 | 1 | 2015 | 6 | 0.030 |
Why?
| | Carcinoma | 2 | 2012 | 240 | 0.030 |
Why?
| | Genes, erbB-1 | 1 | 2015 | 17 | 0.030 |
Why?
| | Transcription, Genetic | 1 | 2002 | 1457 | 0.030 |
Why?
| | Mice, Nude | 1 | 2017 | 698 | 0.030 |
Why?
| | Cell Line, Transformed | 3 | 2000 | 145 | 0.030 |
Why?
| | Lamin Type A | 1 | 2015 | 49 | 0.030 |
Why?
| | Mitogen-Activated Protein Kinase Kinases | 1 | 2015 | 134 | 0.030 |
Why?
| | Child, Preschool | 3 | 2015 | 11074 | 0.030 |
Why?
| | MAP Kinase Kinase 1 | 1 | 2015 | 75 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2018 | 1509 | 0.030 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2015 | 94 | 0.030 |
Why?
| | Consensus | 1 | 2018 | 683 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2017 | 730 | 0.030 |
Why?
| | Sequence Analysis, DNA | 1 | 2017 | 812 | 0.030 |
Why?
| | Respiratory Mucosa | 1 | 2017 | 321 | 0.030 |
Why?
| | Radiopharmaceuticals | 1 | 2015 | 178 | 0.030 |
Why?
| | Fluorodeoxyglucose F18 | 1 | 2015 | 135 | 0.030 |
Why?
| | Recurrence | 1 | 2017 | 1060 | 0.030 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2015 | 382 | 0.030 |
Why?
| | Microdissection | 1 | 2013 | 15 | 0.030 |
Why?
| | Epidermal Growth Factor | 1 | 2013 | 177 | 0.030 |
Why?
| | Animals | 5 | 2019 | 36940 | 0.030 |
Why?
| | Drug Administration Schedule | 1 | 2015 | 786 | 0.030 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2018 | 804 | 0.030 |
Why?
| | Syndecan-4 | 1 | 2012 | 7 | 0.020 |
Why?
| | Disease Management | 1 | 2017 | 628 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2015 | 437 | 0.020 |
Why?
| | Papillomaviridae | 1 | 2013 | 125 | 0.020 |
Why?
| | Cooperative Behavior | 1 | 2015 | 451 | 0.020 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2018 | 1477 | 0.020 |
Why?
| | Transcriptome | 1 | 2018 | 971 | 0.020 |
Why?
| | Bone and Bones | 1 | 2015 | 317 | 0.020 |
Why?
| | SMARCB1 Protein | 1 | 2011 | 31 | 0.020 |
Why?
| | Hyperglycemia | 1 | 2015 | 347 | 0.020 |
Why?
| | Incidence | 1 | 2018 | 2804 | 0.020 |
Why?
| | Green Fluorescent Proteins | 1 | 2012 | 390 | 0.020 |
Why?
| | Chromosomal Proteins, Non-Histone | 1 | 2011 | 126 | 0.020 |
Why?
| | Bronchoscopy | 1 | 2012 | 223 | 0.020 |
Why?
| | Lymphatic Metastasis | 1 | 2012 | 352 | 0.020 |
Why?
| | Mice | 2 | 2019 | 17787 | 0.020 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2013 | 430 | 0.020 |
Why?
| | Pregnancy | 1 | 2023 | 6763 | 0.020 |
Why?
| | Infant | 2 | 2015 | 9465 | 0.020 |
Why?
| | Enzyme Inhibitors | 1 | 2014 | 840 | 0.020 |
Why?
| | Cognition Disorders | 1 | 2014 | 496 | 0.020 |
Why?
| | Retroviridae | 2 | 2000 | 97 | 0.020 |
Why?
| | Reticulocytes | 2 | 1999 | 18 | 0.020 |
Why?
| | Protein Structure, Tertiary | 1 | 2012 | 861 | 0.020 |
Why?
| | Papillomavirus Infections | 1 | 2013 | 325 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2017 | 4193 | 0.020 |
Why?
| | Hypertension | 1 | 2018 | 1295 | 0.020 |
Why?
| | Sex Factors | 1 | 2015 | 2071 | 0.020 |
Why?
| | Leukemic Infiltration | 1 | 2008 | 5 | 0.020 |
Why?
| | Genetic Vectors | 2 | 2000 | 319 | 0.020 |
Why?
| | DNA Primers | 2 | 1999 | 515 | 0.020 |
Why?
| | Human T-lymphotropic virus 1 | 1 | 2008 | 28 | 0.020 |
Why?
| | Rabbits | 2 | 1999 | 794 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2015 | 2844 | 0.020 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2008 | 128 | 0.020 |
Why?
| | In Vitro Techniques | 2 | 1999 | 1092 | 0.020 |
Why?
| | T-Lymphocytes | 1 | 2016 | 1996 | 0.020 |
Why?
| | Phenotype | 1 | 2015 | 3196 | 0.020 |
Why?
| | Apoptosis | 1 | 2015 | 2553 | 0.020 |
Why?
| | Biomarkers | 1 | 2017 | 4149 | 0.010 |
Why?
| | Fibroblasts | 2 | 2000 | 996 | 0.010 |
Why?
| | Transcription Factors | 1 | 2011 | 1719 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2013 | 6079 | 0.010 |
Why?
| | Peptide Chain Termination, Translational | 1 | 2000 | 9 | 0.010 |
Why?
| | Fetal Proteins | 1 | 2000 | 17 | 0.010 |
Why?
| | Genes, Dominant | 1 | 2000 | 96 | 0.010 |
Why?
| | Chromosomes, Human | 1 | 2000 | 44 | 0.010 |
Why?
| | Fibrosarcoma | 1 | 2000 | 22 | 0.010 |
Why?
| | DNA, Complementary | 1 | 2000 | 272 | 0.010 |
Why?
| | Protein Subunits | 1 | 2000 | 239 | 0.010 |
Why?
| | Quinones | 1 | 1999 | 9 | 0.010 |
Why?
| | RNA-Directed DNA Polymerase | 1 | 1999 | 34 | 0.010 |
Why?
| | Lactams, Macrocyclic | 1 | 1999 | 49 | 0.010 |
Why?
| | Benzoquinones | 1 | 1999 | 48 | 0.010 |
Why?
| | Transfection | 1 | 2000 | 945 | 0.010 |
Why?
| | Cyclosporine | 1 | 1999 | 268 | 0.010 |
Why?
| | Carcinoma, Renal Cell | 1 | 2000 | 217 | 0.010 |
Why?
| | Half-Life | 1 | 1997 | 164 | 0.010 |
Why?
| | Molecular Chaperones | 1 | 1999 | 195 | 0.010 |
Why?
| | Neoplasm Proteins | 1 | 2000 | 434 | 0.010 |
Why?
| | RNA, Long Noncoding | 1 | 1999 | 181 | 0.010 |
Why?
| | Adenosine Triphosphate | 1 | 1999 | 491 | 0.010 |
Why?
| | Recombinant Proteins | 1 | 1999 | 1353 | 0.010 |
Why?
| | Skin | 1 | 2000 | 752 | 0.010 |
Why?
| | Flow Cytometry | 1 | 1997 | 1178 | 0.010 |
Why?
| | Prostatic Neoplasms | 1 | 2000 | 1043 | 0.010 |
Why?
|
|
Aisner's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|